Oncolytics Biotech Inc
TSX:ONC
Intrinsic Value
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ONC.
Oncolytics Biotech Inc's market capitalization is 110.9m CAD.
ONC stock price is 1.49 CAD.
ONC.
ONC. Open DCF Valuation
ONC. Open Relative Valuation
ONC has upside potential of 419% compared to the average analyst price target.
Open Wall St Estimates
ONC has negative Free Cash Flow for the last twelve months.
ONC has negative Operating Income for the last twelve months.
ONC has negative Net Income for the last twelve months.
ONC's ROE (Return on Equity) has significantly decreased in the last 3 years from -86% to -103%, and is approaching profitability.
ONC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 672% to -1 554%, and is approaching profitability.
ONC's ROE (Return on Equity) for the past 12 months is negative and is equal to -103%.
ONC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 554%.
ONC's long-term assets (39m CAD) exceed its long-term liabilties (11m CAD).
ONC's D/E (Debt to Equity) is very low and is equal to 0.01.
ONC has negative three-year average ROE (Return on Equity): -92%. The company is not efficient at transforming stockholders' equity into net income.
ONC has negative three-year average ROIC (Return on Invested Capital): -1 116%. The company is not efficient at using invested capital to generate operating income.
ONC's short-term assets (38m CAD) exceed its short-term liabilties (4m CAD).
ONC has negative Net Debt. This means that the company has more cash and short-term investments (35m CAD) than debt (290k CAD).
ONC's Altman Z-Score is very low and is equal to -11.89.
Fundamental Analysis
Oncolytics Biotech Inc
Balance Sheet Decomposition
Oncolytics Biotech Inc
| Current Assets | 38.2m |
| Cash & Short-Term Investments | 34.9m |
| Receivables | 15k |
| Other Current Assets | 3.2m |
| Non-Current Assets | 647k |
| PP&E | 647k |
| Current Liabilities | 4.2m |
| Accounts Payable | 1.1m |
| Accrued Liabilities | 2.5m |
| Other Current Liabilities | 665k |
| Non-Current Liabilities | 7m |
| Long-Term Debt | 290k |
| Other Non-Current Liabilities | 6.7m |
Earnings Waterfall
Oncolytics Biotech Inc
|
Revenue
|
0
CAD
|
|
Operating Expenses
|
-33.8m
CAD
|
|
Operating Income
|
-33.8m
CAD
|
|
Other Expenses
|
6m
CAD
|
|
Net Income
|
-27.8m
CAD
|
Free Cash Flow Analysis
Oncolytics Biotech Inc
ONC Profitability Score
Profitability Due Diligence
Oncolytics Biotech Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Oncolytics Biotech Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
ONC Solvency Score
Solvency Due Diligence
Oncolytics Biotech Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Oncolytics Biotech Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ONC Price Targets Summary
Oncolytics Biotech Inc
According to Wall Street analysts, the average 1-year price target for
ONC
is 7.73 CAD
with a low forecast of 6.06 CAD and a high forecast of 9.45 CAD.
Shareholder Return
ONC Price
Oncolytics Biotech Inc
| Average Annual Return | 9.82% |
| Standard Deviation of Annual Returns | 65.89% |
| Max Drawdown | -82% |
| Market Capitalization | 110.9m CAD |
| Shares Outstanding | 75 419 800 |
| Percentage of Shares Shorted | 0.43% |
Company Profile
Oncolytics Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
You don't have any saved screeners yet
